Crossject

[Editor’s note: This article appeared first in our sister publication, In Vivo .] Although development of Crossject ’s Zeneo began more than 20 years ago, only recently have trials sought to co

Although development of Crossject ’s Zeneo began more than 20 years ago, only recently have trials sought to combine this device with approved drugs. Using its medical device the company is concentra

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Roche Exits Gene Therapy Delivery Pact

To have a big pharma partner end a collaboration or not exercise an option on a lead product are not the death knells they once were for fledgling European biotech companies - at least that’s the expe